Innovative Molecules raises €20 million Series A equity financing round
June 07, 2021 04:00 ET
|
AKAMPION
- Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II - IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies Munich, Germany, June 7, 2021 -...
MerLion Pharmaceuticals Completes Growth Financing Round
May 18, 2021 03:30 ET
|
AKAMPION
- Proceeds will be used to facilitate MerLion`s production and market launch of XtoroTM Berlin, (18/05/2021) - MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research...
ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases
April 12, 2021 03:45 ET
|
AKAMPION
- Company forms international consortium with ProteoGenix SAS and Amsterdam UMC Schlieren (Zurich Area), Switzerland – April 12, 2021 – ImmunOs Therapeutics AG, a Swiss bio-technology company...
T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer
April 07, 2021 06:00 ET
|
AKAMPION
San Francisco, CA / Berlin, Germany – April 7, 2021 — T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for the benefit of solid tumor patients...
SEQ-IT vermeldet Durchbruch in der schnellen Variantendiagnostik von SARS-CoV-2
February 22, 2021 04:00 ET
|
AKAMPION
Kaiserslautern, Deutschland, 22. Februar 2021 – SEQ-IT, ein führender Anbieter von molekularen Dienstleistungen, gibt die Entwicklung eines neuartigen Massenspektrometrie-basierten Tests für den...
SEQ-IT reports breakthrough in the rapid variant diagnosis of SARS-CoV-2
February 22, 2021 04:00 ET
|
AKAMPION
Kaiserslautern, Germany, February 22, 2021 – SEQ-IT, a leading molecular services provider, today announced they completed a novel mass spectrometry based rapid test for the detection of 20 of the...
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer
January 19, 2021 06:00 ET
|
AKAMPION
San Francisco, CA / Berlin, Germany – January 19, 2021 — T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to...
Cardior Pharmaceuticals gibt positive Phase Ib Ergebnisse von CDR132L bei Herzinsuffizienz bekannt
November 12, 2020 03:05 ET
|
AKAMPION
Erste Substanz aus neuer Wirkstoffklasse zeigt ausgezeichnete Verträglichkeit und SicherheitEinzigartiger Wirkmechanismus bei Herzinsuffizienz durch Herzfunktionsdaten und Biomarker bestätigtPhase II...
Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
November 12, 2020 03:05 ET
|
AKAMPION
First-in-class compound showed excellent tolerability and safety Unique mode of action in chronic heart failure confirmed by data on cardiac function and biomarkersPhase II studies in subacute and...
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
September 21, 2020 04:00 ET
|
AKAMPION
BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid...